Search

Displaying results 2411 - 2420 of 2950 in total
  1. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    Linzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. … [A253642,A253647] It is similar to other GnRH receptor antagonists like [cetrorelix], [relugolix], and [elagolix].

    Categories: Gonadotropin Releasing Hormone Receptor Antagonists, Cytochrome P-450 Substrates
  2. Drug

    Norclobazam

    go.drugbank.com/drugs/DB17092
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  3. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    Ziftomenib is a potent and highly selective menin inhibitor. This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation wh...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  4. Drug

    Redaporfin

    go.drugbank.com/drugs/DB17219
    Investigational

    Categories: P-glycoprotein substrates
  5. Drug

    P-BCMA-101

    go.drugbank.com/drugs/DB17371
    Investigational

    P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.

  6. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of a...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  7. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    Vimseltinib is a small molecule kinase inhibitor targeting colony-stimulating factor 1 receptor (CSF1R).

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    Rilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    Linafexor

    go.drugbank.com/drugs/DB18031
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Gunagratinib

    go.drugbank.com/drugs/DB18191
    Experimental

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates